Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C

• Status: Completed
• Trial end date: 2006-01-01
• Target enrollment: 0
• Participant gender: All

Summary

There is evidence on the beneficial effects of the administration of angiotensin II type 1 (AT1) receptors antagonists on liver fibrosis in hepatic stellate cells, experimental models of liver fibrosis in rodents and limited information in chronic hepatitis C with mild fibrosis.

The purpose of this study is to investigate the effect of long-term administration of oral Losartan, an AT1 receptor antagonist, on liver fibrogenesis in patients with chronic hepatitis C and fibrosis F2-F3 (METAVIR score).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Clinic of Barcelona
• Treatments: Losartan

Criteria

Inclusion Criteria:

• age between 35 and 65 years

• chronic hepatitis C with intermediate fibrosis (F2-F3 in Metavir score).

• non-responder or contraindication to antiviral therapy.

Exclusion Criteria:

• any other cause of liver disease

• HIV positive

• alcohol consumption

• arterial hypertension

• creatinine > 1.5mg/dL

• treatment with AT1 receptor antagonists or angiotensin converting enzyme inhibitors in the past 12 months.

• antiviral therapy in the past 12 months

• contraindications to oral losartan